| Ytd | 1.17% | |
| 1y | -35.69% |
| Open | 5.00 | Prev Close | 4.95 | Low | 4.98 | High | 5.26 | Mkt Cap | 1.85B |
| Vol | 1.25M | Avg Vol | 987.41K | EPS | -0.62 | P/E | N/A | Forward P/E | 22.73 |
| Beta | 0.18 | Short Ratio | 6.39 | Inst. Own | 11.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 3.77 | 200-d Avg | 4.15 | 1yr Est | 6.00 |
ALVO News
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology comp
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology co
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess
US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jum
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Monday.
The text discusses recent gains in the stock market, particularly for companies like Napco Security
B of A Securities analyst Jason Gerberry initiates coverage on Alvotech (NASDAQ:ALVO) with a Buy
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global bi
Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges
Alvotech (ALVO) Q2 2026 Earnings Call Transcript
Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown
Alvotech (NASDAQ:ALVO) reported second-quarter financial results on Thursday. The transcript from th
Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimat
Alvotech (NASDAQ:ALVO) reported quarterly losses of $(0.17) per share which missed the analyst conse
Alvotech (NASDAQ:ALVO) affirms FY2026 sales outlook from $650.000 million-$700.000 million to $650.0
REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company
REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) ("Alvotech"
REYKJAVIK, ICELAND (August 10, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global
U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo
Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share.
Alvotech (NASDAQ:ALVO, ALVO-SDB))) (the "Company"), a global biotechnology company specializ
REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Compan
Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financi
— $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Mana
REYKJAVIK, ICELAND (July 1, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology compan
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (
REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech”
REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”
US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings;
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open
REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”
Alvotech (NASDAQ:ALVO, ALVO-SDB))) ("Alvotech" or the "Company"), a global biotechno
REYKJAVIK, Iceland, June 15, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech”
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (
Alvotech (NASDAQ:ALVO) reported quarterly sales of $105.900 million which missed the analyst consens
U.S. stock futures down, Nasdaq 100 falls over 100 points. Mach Natural Resources LP (MNR) shares di
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result
UBS analyst Ashwani Verma maintains Alvotech (NASDAQ:ALVO) with a Buy and lowers the price target
Barclays analyst Glen Santangelo maintains Alvotech (NASDAQ:ALVO) with a Underweight and lowers t
Alvotech (NASDAQ:ALVO) reported quarterly sales of $173.200 million which beat the analyst consensus
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 com
https://www.cms.gov/priorities/medicare-prescription-drug-affordability/overview/medicare-drug-price
Barclays analyst Glen Santangelo initiates coverage on Alvotech (NASDAQ:ALVO) with a Underweight